The appraisals of carfilzomib in combination with lenalidomide and dexamethasone for relapsed multiple myeloma [ID677] and carfilzomib in combination with dexamethasone for relapsed multiple myeloma [ID934] were scheduled into the NICE work programme as two separate appraisals because of the difference in timing of their respective marketing authorisations. For information, NICE has agreed to the company’s request that these two appraisals now be considered as one Single Technology Appraisal as the evidence base for the proposed marketing authorisation for carfilzomib in combination with dexamethasone will be important in supporting the cost effectiveness of carfilzomib for the broader relapsed/refractory setting. The evidence base for carfilzomib in combination with lenalidomide and dexamethasone for previously treated multiple myeloma is based on the phase III study, ASPIRE.
 
Status Discontinued
Process STA pre-2018
Referral date 01 March 2015

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Project lead Jeremy Powell

Timeline

Key events during the development of the guidance:

Date Update
07 April 2016 Discontinued, The appraisals of carfilzomib in combination with lenalidomide and dexamethasone for relapsed multiple myeloma [ID677] and carfilzomib in combination with dexamethasone for relapsed multiple myeloma [ID934] were scheduled into the NICE work programme as two separate appraisals because of the difference in timing of their respective marketing authorisations. For information, NICE has agreed to the company’s request that these two appraisals now be considered as one Single Technology Appraisal as the evidence base for the proposed marketing authorisation for carfilzomib in combination with dexamethasone will be important in supporting the cost effectiveness of carfilzomib for the broader relapsed/refractory setting. The evidence base for carfilzomib in combination with lenalidomide and dexamethasone for previously treated multiple myeloma is based on the phase III study, ASPIRE.
15 January 2016 Suspended: This appraisal has been suspended because the manufacturer of carfilzomib has informed NICE it will not be able to make a submission for this appraisal. Our normal procedure in these circumstances is to publish termination guidance.
28 October 2015 Invitation to participate
09 October 2015 Please note that following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during mid October 2015 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid December 2015.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance